A record of what Motilal Oswal Analysis said publicly, with the source. Not advice.
“Motilal Oswal maintains a BUY stance on Gland Pharma, citing a target price of ₹3,690 that represents an upside of up to 16% from current levels. The firm highlights expected 14%/20%/21% CAGR in revenue, EBITDA and PAT over FY26‑28 driven by higher volume from new products and increased off‑take of existing ones, underpinning the bullish outlook.”
Motilal Oswal Analysis’s track record (trackable calls only): 453 graded calls · 95% CI 36–45%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹3,690, as stated.
Window: 12 months, the default when no time frame is stated.
Window still open: no verdict until a close reaches a level or the window ends.
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.